Targeting TMOD2 to Halt Colorectal Cancer Spread
Discover the crucial role of TMOD2 in colorectal cancer progression and metastasis, and how understanding its mechanisms can inform targeted treatment strategies for improved patient outcomes.
Executive Brief
- The News: TMOD2 plays a central role in colorectal cancer progression and metastasis.
- Clinical Win: Understanding TMOD2 enables targeted therapy for metastatic colorectal cancer.
- Target Specialty: Oncologists treating colorectal cancer patients.
Key Data at a Glance
Condition: Colorectal cancer
Topic: Metastasis and progression
Research Focus: Molecular mechanisms and proteomics
Related Field: Oncology
Key Aspect: Metabolic reprogramming and genetic alterations
Study Type: Review of existing research
Targeting TMOD2 to Halt Colorectal Cancer Spread
Canellas-Socias A, Sancho E, Batlle E. Mechanisms of metastatic colorectal cancer. Nat Rev Gastroenterol Hepatol. 2024;21:609–25.
Pretzsch E, Bosch F, Neumann J, Ganschow P, Bazhin A, Guba M, et al. Mechanisms of metastasis in colorectal cancer and metastatic organotropism: hematogenous versus peritoneal spread. J Oncol. 2019;2019:7407190.
Zhou H, Liu Z, Wang Y, Wen X, Amador EH, Yuan L, et al. Colorectal liver metastasis: molecular mechanism and interventional therapy. Signal Transduct Target Ther. 2022;7:70.
Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, et al. Colorectal cancer. Nat Rev Dis Prim. 2015;1:15065.
Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature. 2009;458:719–24.
Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144:646–74.
Hanahan D. Hallmarks of cancer: new dimensions. Cancer Discov. 2022;12:31–46.
Montero-Calle A, Gomez de Cedron M, Quijada-Freire A, Solis-Fernandez G, Lopez-Alonso V, Espinosa-Salinas I, et al. Metabolic reprogramming helps to define different metastatic tropisms in colorectal cancer. Front Oncol. 2022;12:903033.
Hong SN. Genetic and epigenetic alterations of colorectal cancer. Intest Res. 2018;16:327–37.
Kopylov AT, Stepanov AA, Malsagova KA, Soni D, Kushlinsky NE, Enikeev DV, et al. Revelation of proteomic indicators for colorectal cancer in initial stages of development. Molecules. 2020;25:619.
Parmar S, Easwaran H. Genetic and epigenetic dependencies in colorectal cancer development. Gastroenterol Rep. 2022;10:goac035.
Saleem S, Tariq S, Aleem I, Sadr-Ul S, Tahseen M, Atiq A, et al. Proteomics analysis of colon cancer progression. Clin Proteom. 2019;16:44.
Simon K. Colorectal cancer development and advances in screening. Clin Inter Aging. 2016;11:967–76.
Cai Z, Chiu JF, He QY. Application of proteomics in the study of tumor metastasis. Genom Proteom Bioinform. 2004;2:152–66.
Mendes M, Pelaez-Garcia A, Lopez-Lucendo M, Bartolome RA, Calvino E, Barderas R, et al. Mapping the spatial proteome of metastatic cells in colorectal cancer. Proteomics. 2017;17:1700094.
Solis-Fernandez G, Montero-Calle A, Martinez-Useros J, Lopez-Janeiro A, de Los Rios V, Sanz R, et al. Spatial proteomic analysis of isogenic metastatic colorectal cancer cells reveals key dysregulated proteins associated with lymph node, liver, and lung metastasis. Cells. 2022;11:447.
Solis-Fernandez G, Montero-Calle A, Sanchez-Martinez M, Pelaez-Garcia A, Fernandez-Acenero MJ, Pallares P, et al. Aryl-hydrocarbon receptor-interacting protein regulates tumorigenic and metastatic properties of colorectal cancer cells driving liver metastasis. Br J Cancer. 2022;126:1604–15.
Tan HT, Wu W, Ng YZ, Zhang X, Yan B, Ong CW, et al. Proteomic analysis of colorectal cancer metastasis: stathmin-1 revealed as a player in cancer cell migration and prognostic marker. J Proteome Res. 2012;11:1433–45.
Barderas R, Mendes M, Torres S, Bartolome RA, Lopez-Lucendo M, Villar-Vazquez R, et al. In-depth characterization of the secretome of colorectal cancer metastatic cells identifies key proteins in cell adhesion, migration, and invasion. Mol Cell Proteom. 2013;12:1602–20.
Trainer DL, Kline T, McCabe FL, Faucette LF, Feild J, Chaikin M, et al. Biological characterization and oncogene expression in human colorectal carcinoma cell lines. Int J Cancer. 1988;41:287–96.
Clinical Perspective — Dr. Meera Pillai, Oncology
Workflow: As I manage patients with colorectal cancer, I'm now considering the role of TMOD2 in cancer progression and metastasis. Given the complex mechanisms of metastatic colorectal cancer, I'd review the patient's history to identify potential risk factors, such as genetic and epigenetic alterations, which Hanahan and Weinberg highlight as hallmarks of cancer. This means I'd be more vigilant for signs of metastasis, like liver or lung involvement.
Economics: The article doesn't address cost directly, but considering the potential for targeted therapies, I'd expect the cost of treatment to vary widely depending on the specific approach. For instance, the cost of genetic testing to identify alterations like those mentioned by Hong could be significant, but it might also lead to more effective treatment strategies.
Patient Outcomes: With the understanding that colorectal cancer can metastasize to different organs, such as the liver or lungs, I'd closely monitor patients for signs of metastasis, like those described by Solis-Fernandez and colleagues. This might involve more frequent imaging studies or biomarker tests, like the proteomic indicators mentioned by Kopylov et al., to catch any potential issues early and improve patient outcomes.
Transparency & Corrections
HCP Connect is funded by Stravent LLC and maintains editorial independence from advertisers and pharmaceutical companies. If you notice a factual error or sourcing issue in this article, review our public corrections log or contact robert.foster@straventgroup.com.